Company Profile
Intra-Cellular Therapies Stock Price, News & Analysis
- Ticker:
- ITCI
- Exchange:
- NASDAQ
- Sector:
- Biotechnology
- Location:
- United States
Stock performance
131.87 USD
Close
Last updated: April 1, 2025 at 00:00
—
Market cap
Why the stock is moving
ITCI is trading with a steady catalyst profile while investors wait for the next headline that changes the story.
Company overview
Business overview
Intra-Cellular Therapies is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Intra-Cellular Therapies is followed within the biopharmaceutical universe for its exposure to pipeline and commercialization catalysts.
Business Model Characteristics
Intra-Cellular Therapies follows a pipeline-led model where clinical readouts, filing updates, and program expansion determine how the market underwrites the story.
Position Within the Biotechnology Landscape
Compared with more mature healthcare names, Intra-Cellular Therapies sits on the development side of the biotech landscape, where catalyst timing can reprice the stock quickly.
Future catalysts
Recent news
The five most recent related feed items are shown below in reverse chronological order.
- 01
Zimmer Biomet Names Chintan Desai President of Asia Pacific Region
ZBH · Source: Zimmer Biomet
- 02
Zimmer Biomet Announces Webcast and Conference Call of Second Quarter 2026 Financial Results
ZBH · Source: Zimmer Biomet
- 03
U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Mezigdomide in Patients with Relapsed or Refractory Multiple Myeloma
BMY · Source: BMYBristol-Myers Squibb Company
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Intra-Cellular Therapies (ITCI)?
Intra-Cellular Therapies (ITCI) most recently closed at 131.87 USD.
What does Intra-Cellular Therapies do?
Intra-Cellular Therapies is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.
On which exchange is ITCI stock listed?
Intra-Cellular Therapies (ITCI) is associated with NASDAQ, United States, Biotechnology.
What is Intra-Cellular?
Intra-Cellular Therapies is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.
Which conditions is Intra-Cellular Therapies targeting with Intra-Cellular?
Intra-Cellular Therapies is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.
What is Therapies?
Intra-Cellular Therapies is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.